Consap
- User: Female
- Hormonal: Non-Hormonal
-
Delivery type:
- Multiple
- Vaginal Gel
- Vaginal - Other
-
Intended Duration:
- Pericoital
- Development Stage: Single-Country Approval
- Developer(s)/researcher(s): Central Drug Research Institute, India, HLL Lifecare Limited
Details
- API: Saponins
- Target: Not Yet Determined
-
Mechanism of Action:
- Inhibition of Sperm Motility
- Regimen: On Demand
- MPT: Potential MPT
- Promising Attributes: Developers note a strong interest in Indian context in user-controlled non-hormonal pericoital methods. Consap is thought to be minimally irritating.
Product Status
Single-Country Approval: India
History
1995: Results from pre-clinical evaluation of saponins as a potential spermicide published
2003: Phase III trial for CONSAP, a spermicidal cream developed from the plant Sapindus Mukorosii, concludes. In vitro evaluation ongoing.
2004: CONSAP approved by Indian regulatory authorities & licensed to HLL
2013: New Phase IIIa trial results published - Pearl index of 2.3 for 470 study participants followed over 6 months
2015: "Pilot Study" with 27 participants shows consistently immobilized sperm with minimal side effects